Dendright is a clinical-stage biotechnology company developing DEN-181, a first-in-class tolerizing immunotherapy for the treatment of rheumatoid arthritis.
DEN-181 targets the underlying cause of the disease rather than treating its inflammatory symptoms. It is a nanoparticle-based immunotherapy designed to regulate activated immune cells which cause inflammation, pain and joint damage in rheumatoid arthritis. Laboratory studies have shown that activated immune cells can be regulated in an antigen-specific manner through nanoparticle delivered signals. DEN-181 has the potential to offer higher specificity of effect and lower toxicity than current treatments for RA given the lack of broadly suppressive effects on the immune system.
Dendright entered into a R&D Collaboration and Option to License Agreement with Janssen Biotech, Inc. in 2013 which was extended in 2017. In 2017, Dendright entered into an agreement with Arthritis Queensland to also contribute funding to the clinical program.
Dendright’s core technology patent, which describes the particulate co-delivery of target antigens and NF-kB inhibitors to immune cells, was granted by the United States Patent and Trademark Office (USPTO) as US Patent Application 12/444,790 in 2015. Dendright has also secured the grant of related patents in Australia, Canada and China.
The founding technology was discovered and developed by Professor Ranjeny Thomas at the University of Queensland Diamantina Institute. Dendright is a start-up company of UniQuest, the technology transfer and commercialisation company of the University of Queensland.
Company Details
- Founded
- -
- Address
- Level 7, Gps Building, Staff House Road, St Lucia, Brisbane,queensland 4069,australia
- Industry
- Biotechnology
- Website
- dendright.com.au
- HQ
- Brisbane, Queensland
Dendright Pty Limited Questions
Dendright Pty Limited's website is dendright.com.au
Dendright Pty Limited's LinkedIn profile is https://au.linkedin.com/company/dendright-pty-limited
Dendright Pty Limited's industry is
Biotechnology
Dendright Pty Limited's top competitors are
Axonis Therapeutics,
Cytiva,
Lantern Pharma Inc. (Nasdaq: Ltrn),
Rona Therapeutics,
Resolian,
Biocurate Pty Ltd,
Granata Bio,
Lifordi Immunotherapeutics, Inc.,
Rznomics Inc.,
Notaz.
Dendright Pty Limited's categories are Biotechnology
Dendright Pty Limited's founding year is 2005
